Floatz logo

21.15.gpc3-car t cells

Rhabdomyosarcoma

Baylor College of MedicineCell therapyPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

58 Active assets in the Rhabdomyosarcoma cohort.

Asset / SponsorPhaseRating
Ipilimumab
Children's National Research Institute
Phase 2BB
CALCIUM PHOSPHATE
Children's Oncology Group
Phase 3BB
Irinotecan
Milton S. Hershey Medical Center
Phase 2BB
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
Cixutumumab
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

21.15.gpc3-car t cells is also rated in:

hepatoblastomaDormant
CC
Indicative ·
43 / 100
View asset →
atypical teratoid rhabdoid tumorDormant
CC
Indicative ·
43 / 100
View asset →
Wilms tumorDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →